Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives

Author(s): Juan J. Rodriguez, Oscar C. Munoz*, Mateo Porres-Aguilar, Debabrata Mukherjee

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 21 , Issue 1 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.

Keywords: COVID-19, thrombosis, thromboembolism, venous thromboembolism, thromboprophylaxis, bleeding, stroke, myocardial infarction, pulmonary embolism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 15 March, 2021
Page: [23 - 29]
Pages: 7
DOI: 10.2174/1871529X21666210315123347
Price: $65

Article Metrics

PDF: 357